Complex Oncological Center Plovdiv EOOD

The Complex Oncological Center Plovdiv EOOD conducts extensive research on advanced solid tumors, aiming to evaluate innovative targeted and immunotherapy approaches that may improve survival and quality of life for patients.

• Advanced breast cancer
• Advanced non‑small cell lung cancer
• Metastatic ovarian cancer
• Colorectal cancer with BRAF V600E mutation
• Renal cell carcinoma
• Muscle‑invasive bladder cancer

With 41 ongoing trials and a team of 12 investigators, the site is a hub for testing new therapies across multiple solid tumor types.

Researchers at the center focus on blood‑related cancers, exploring novel agents and combination regimens to enhance treatment efficacy for patients with aggressive disease.

• Acute myeloid leukemia
• Myelodysplastic syndrome
• Chronic myelomonocytic leukemia
• Diffuse large B‑cell lymphoma
• Follicular lymphoma
• Acute lymphoblastic leukemia

The program evaluates emerging targeted therapies and immunomodulators to address unmet needs in hematologic oncology.

The department advances prostate cancer care by testing hormonal strategies and DNA‑repair targeting agents, seeking to prolong progression‑free survival in both castration‑sensitive and castration‑resistant settings.

• Metastatic castration‑sensitive prostate cancer
• Castration‑resistant prostate cancer
• PTEN‑deficient metastatic hormone‑sensitive prostate cancer
• HRR‑mutated prostate cancer
• High tumor‑load prostate cancer
• Prostate cancer with PTEN loss

Ongoing trials evaluate combinations such as PARP inhibitors with androgen deprivation therapy to improve outcomes.

Studies target ovarian, fallopian tube, peritoneal, and endometrial cancers, aiming to refine the use of PARP inhibitors, antibody‑drug conjugates, and immunotherapy for better disease control.

• BRCA‑mutated ovarian cancer
• Platinum‑sensitive relapsed ovarian cancer
• High‑grade serous ovarian carcinoma
• Endometrial cancer
• Uterine cancer
• Ovarian cancer with HRD

The site integrates biomarker‑driven trials to personalize therapy for women with gynecologic malignancies.

A dedicated program investigates both non‑small cell and small‑cell lung cancers, focusing on KRAS‑mutated, HER2‑positive, and PD‑L1‑high tumors to assess novel targeted‑immunotherapy combos.

• KRAS‑mutated non‑small cell lung cancer
• HER2‑positive NSCLC
• Extensive‑stage small‑cell lung cancer
• Limited‑stage small‑cell lung cancer
• PD‑L1 high NSCLC
• NSCLC with BRAF mutation

Trials assess agents such as KRAS inhibitors, HER2‑directed antibodies, and checkpoint inhibitors to extend survival.

Research includes renal cell carcinoma and urothelial carcinoma, evaluating checkpoint inhibitors and combination regimens to improve response rates in these malignancies.

• Renal cell carcinoma
• Locally advanced urothelial carcinoma
• Metastatic urothelial carcinoma
• Kidney cancer
• Bladder cancer

The program explores synergistic effects of immunotherapy with targeted agents and chemotherapy.

The center evaluates therapies for head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma, seeking to enhance response through immunotherapy and novel biologics.

• Head and neck squamous cell carcinoma
• Cutaneous squamous cell carcinoma
• Advanced skin cancer
• HPV‑related oropharyngeal cancer
• Recurrent head and neck cancer

Ongoing studies compare checkpoint blockade alone versus combined with investigational agents.

Beyond tumor‑focused trials, the site investigates metabolic, nutritional, and physiological phenomena that influence cancer progression and patient resilience.

• Cancer‑associated cachexia
• Metabolic alterations in tumor microenvironment
• Nutritional support in oncology
• Genetic biomarkers for therapy response
• Microbiome influence on immunotherapy
• Physiological monitoring of treatment tolerance

These studies aim to optimize supportive care and identify predictive markers that guide personalized treatment.